WHO Adds Rare Disease Treatments to the Essential Medicines List
Salome Mekhuzla, Director of Global Development at the World Federation of Hemophilia, reposted from Rare Diseases International on LinkedIn:
”Thrilled to have contributed to this project and congratulations to RDI team on all the work accomplished.”
Quoting Rare Diseases International‘s post:
”New Report Published!
With the publication of the updated WHO Model List of Essential Medicines (EML) and the Model List for Children (EMLc), important progress has been made: for the first time, treatments for several rare diseases have been included. This achievement highlights how advocacy and active engagement are vital to ensure that more therapies for rare diseases are recognized as essential in the future. In this context, RDI is proud to share the publication of the Essential Medicines Working Group (EMWG) Report.
This report, developed by RDI’s Essential Medicines Working Group, explores:
- Successful and unsuccessful applications for rare disease medicines to the EML, identifying challenges, success factors, and opportunities to strengthen the evaluation process for essential RD medicines.
- Concrete recommendations and a Call-to-Action to strengthen the EML’s impact for people living with rare diseases globally.
This work would not have been possible without the invaluable contributions of the members of the RDI Essential Medicines Working Group and the organizations that generously shared their experiences. Special thanks to all contributors for their dedication and insights. This project was developed by RDI Global Programme: Chiuhui Mary Wang, Chiara Tovani and Sara Brambilla.
Read the full report here․
For more information, check our website․”
Stay updated with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic